Truist Securities has increased its price target for Tenet Healthcare to $305 from $290, while maintaining a Buy rating. This adjustment follows the company's recent third-quarter 2026 earnings call, indicating a positive re-evaluation of the company's prospects by the analyst firm.
Truist Securities has raised its price target for Tenet Healthcare (THC) to $305 from $290, while reiterating its 'Buy' rating. This positive adjustment comes after the company's Q3 2026 earnings call, suggesting that the analyst firm found the results or outlook presented to be favorable. For traders, this indicates a potential short-term positive sentiment boost for THC, as an increased price target from a reputable firm often signals confidence in future performance. The long-term implication is that analysts believe the company has further upside potential. The key opportunity for traders lies in the potential for the stock to move towards this new, higher price target, driven by renewed investor interest.